Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR / GLP ‐ 1R agonist survodutide in mice

Documenti analoghi

• Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
  di: Carel W. le Roux, et al.
  Pubblicazione: (2025)
• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  di: Hans Johnson, et al.
  Pubblicazione: (2025)
• The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
  di: Zbigniew Siudak, et al.
  Pubblicazione: (2025)
• Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta‐analysis
  di: Ya‐Jun Xiao, et al.
  Pubblicazione: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)